Last reviewed · How we verify
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Details
| Lead sponsor | Telik |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 28 |
| Start date | 2002-10 |
| Completion | 2004-09 |
Conditions
- Carcinoma, Non-small-cell Lung
Interventions
- TLK286 in combination with docetaxel
Countries
United States